Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.

Fiche publication

Date publication

mars 2017

Journal

BMC medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AVEROUS Gerlinde , Pr BACHELLIER Philippe , Pr NAMER Izzie-Jacques

Tous les auteurs :
Battini S, Faitot F, Imperiale A, Cicek AE, Heimburger C, Averous G, Bachellier P, Namer IJ

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28298227

Résumé

Pancreatic adenocarcinomas (PAs) have very poor prognoses even when surgery is possible. Currently, there are no tissular biomarkers to predict long-term survival in patients with PA. The aims of this study were to (1) describe the metabolome of pancreatic parenchyma (PP) and PA, (2) determine the impact of neoadjuvant chemotherapy on PP and PA, and (3) find tissue metabolic biomarkers associated with long-term survivors, using metabolomics analysis.